Xenon Pharmaceuticals (XENE) Stock Rockets 40% on Breakthrough Epilepsy Trial Results - Blockonomi

Shares of Xenon Pharmaceuticals climbed 40% following successful Phase 3 X-TOLE2 trial results showing azetukalner achieved its primary endpoint across both dosing cohorts. • The higher 25 mg dosage r... [3689 symbols]

Últimos artigos